Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer’s Gilotrif/Giotrif, but the new asset is far behind competitors from AstraZeneca and Clovis.

Advertisement

Related Content

Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register